阿德罗宾对败血症诱导的心肌病的保护作用
Ji Wu1, Zu-Xiang Wu2, Huan Hu2
1Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang of Jiangxi, China, No. 1 Minde Road, Nanchang, Jiangxi 330006, China; Department of Cardiovascular Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou of Jiangxi, China, No. 128, Jinling Road, Ganzhou, Jiangxi 341000, China.
International immunopharmacology
|December 14, 2025
概括
通过减少炎症,亡和氧化应激,阿德罗治疗可以预防败血症引起的心肌病. 这种可以增强心脏功能,并可能为这种关键疾病提供一种新的治疗策略.
科学领域:
- 心血管医学 心血管医学
- 分子生物学分子生物学
- 败血症研究 败血症研究
背景情况:
- 败血症诱导的心肌病 (SIMD) 显著增加败血症患者的死亡率.
- 目前,没有针对SIMD的向疗法.
- 阿德罗具有与心血管健康相关的抗炎,抗氧化和抗丧性质.
研究的目的:
- 调查阿德罗宾在败血性心肌病中的保护作用.
- 阐明阿德罗在SIMD中的作用的潜在机制.
主要方法:
- 在败血症心肌病数据集中对能量恒温相关基因 (ENHO) 的差异基因表达分析.
- 在脂聚糖 (LPS) 诱导的心肌损伤的小鼠模型中验证.
- 使用分子和组织学技术评估心脏功能,心肌病理,炎症,亡和氧化应激标志物.
- 用核因素红色素-2 (Nrf2) 抑制剂 (ML385) 进行救援实验,以探索机械路径.
主要成果:
- 在败血性心肌病中,阿德罗的表达减少.
- 外源性阿德罗的使用改善了心脏功能,并减少了LPS治疗小鼠和细胞的心肌损伤.
- 阿德罗平治疗降低了对抗亡的蛋白质Bax和上调了对抗亡的蛋白质Bcl-2.
- 氨酸减少了炎症因素 (TNF-α,IL-6,IL-1β) 和减少了氧化应激 (ROS),同时增加了抗氧化蛋白 (NQO1,GPX1,Nrf2).
- 抑制Nrf2取消了阿德罗宾对抗氧化蛋白表达的有益作用.
结论:
- 亚德罗宾通过抗炎,抗亡和抗氧化机制,防止败血性心肌病.
- 氨酸通过激活Nrf2/抗氧化剂反应元件 (ARE) 信号通路来减轻LPS诱导的心肌损伤.
- 阿德罗在败血症引起的心肌病症中显示出临床应用的显著治疗潜力.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879